The FDA's approval is based on the results of the FLOW phase 3b kidney outcomes trial. The trial revealed that Ozempic® 1 mg significantly lowered the relative risk of worsening kidney disease, kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback